Active	Status	Sponsor type	Region	Phase	Filter
11 Active 0 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Meyhöfer, Sebastian
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes	Active, not recruiting	3	1500	Europe, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Type 2 Diabetes	08/25	08/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
NCT03525002 / 2017-003387-12: Dopamine Action on Metabolism in Relation to Genotype	Recruiting	2	150	Europe	Bromocriptine, Placebo	University Hospital Tuebingen, University Hospital of Cologne, University Hospital Lübeck	Obesity	12/24	06/25
MERCAU, GUILLERMO ADOLFO
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
NCT05565742: A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]	Completed	2	320	Europe, Japan, US, RoW	LY3819469, Placebo	Eli Lilly and Company	Lipoprotein Disorder	10/23	10/24
Sgarbi, José Augusto
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease	Recruiting	3	1200	Europe, Canada, Japan, US, RoW	Remternetug, LY3372993, Placebo	Eli Lilly and Company	Alzheimer's Disease	04/29	10/30
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes	Active, not recruiting	3	1500	Europe, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Type 2 Diabetes	08/25	08/25
Meyhöfer, Svenja
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29